Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue ...

Environmental and Occupational Exposure: Chronic inhalation of inorganic and organic particulates, such as silica, asbestos, ...

Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to ...

Wang was expected to have a bilateral meeting with External Affairs Minister S Jaishankar of India on the sidelines of a BRICS meeting at Rio de Janeiro in Brazil. But Jaishankar, as well as NSA ...

Niktimvo is the first anti-CSF1R antibody approved to target the inflammation and fibrosis associated with chronic GVHD and we are already seeing the impact it is having for patients giving us ...

Turkish Military Delegation Holds Talks With Pak Air Force Chief Amid Tensions With India Amid escalating tensions between India and Pakistan after the deadly ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

1 Non-GAAP cost of product revenues excludes the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and ...

Introduction Interstitial lung disease (ILD) patients may develop a progressive phenotype usually characterised by ...